Chromogranin A assay in clinical practice

Area of Science:

• Neuroendocrinology
• Biochemistry
• Oncology

Background:

• Chromogranins are a protein family found in neuroendocrine secretory vesicles.
• Chromogranin A (CgA) is the primary component, functioning as a prohormone that generates active peptides.
• CgA exhibits auto, para, and endocrine functions and is a widely used immunohistochemical marker.

Purpose of the Study:

• To review the utility of Chromogranin A (CgA) determination in the diagnosis and follow-up of endocrine tumors.
• To discuss emerging clinical applications of CgA, including stress evaluation and cardiovascular risk assessment.
• To highlight the ongoing development of novel assays for active peptide concentrations.

Main Methods:

• Review of existing literature and studies on Chromogranin A (CgA) assays and clinical applications.
• Analysis of factors influencing CgA interpretation, such as tumor localization and co-existing conditions.
• Discussion of the current status and future directions of CgA measurement technologies.

Main Results:

• Despite variability in standardization and cut-off levels, some CgA assays demonstrate reliability.
• Plasma CgA levels generally correlate with tumor mass, supporting its role in monitoring endocrine tumors.
• Interpretation requires consideration of tumor origin, hormonal co-secretions, renal function, and hypergastrinemia.

Conclusions:

• Chromogranin A (CgA) remains a valuable marker for endocrine tumor diagnosis and management.
• New clinical applications in critical care and cardiovascular risk are emerging.
• Advancements in assay development promise more precise measurement of active CgA-derived peptides.